Turner Construction has announced the topping out of McGivney Tower, which marked the conclusion of vertical construction for ...

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

Jupiter Neurosciences (JUNS) issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product ...

Klotho Neurosciences, Inc., a biotech firm specializing in biological products with a current market capitalization of $9.35 million, has entered into a securities purchase agreement securing $2 ...

This study reveals the key role of microglia, brain’s immune cells, in brain metastases progression and identifies a strategy ...

Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 59.50%, which has investors questioning if this is right time to ...

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical ...

Jupiter Neurosciences董事长兼首席执行官Christer Rosén强调与Catalent合作的重要性，称赞其"领先业界的制药生产专业知识"以及高效扩大生产规模的能力。这一步骤被认为对推进JOTROL™进入帕金森病的临床开发阶段至关重要。